Gericke has launched the Gericke Formulation Skid GFS Gen3, a new continuous manufacturing platform for the formulation of OSD (oral solid dosage). It is designed to speed up pharmaceutical production, making it simpler and safer. 

“At its core, GFS Gen3 reflects a different way of thinking about continuous manufacturing,” said Bernhard Meir, Head of Continuous Manufacturing of OSD, Gericke. “We designed the platform so that containment, precision, and regulatory readiness reinforce each other — giving teams confidence as they progress, without unnecessary disruption.” 

The platform supports a single continuous manufacturing approach, keeping progress from early trials to long-term production in one platform architecture. This means pharmaceutical companies don’t need to switch between different equipment, keeping up momentum and shortening the path between development to patient.  

The platform keeps things simple, with a focus on consistency and reducing variability, supporting reliable performance over the lifecycle of a product.  

To support safety, compliance and smooth production, GEN-3 incorporates scalable containment options such as basic dust control to advanced high containment solutions.  

“We deliberately avoided designing a rigid system,” added Bernhard. “GFS Gen3 supports controlled evolution over time — recognising that pharmaceutical manufacturing must be able to move forward without starting over.” 

Find out more on Gericke’s website: https://www.gerickegroup.com/